| 1751 |
LUCIMITO |
MITOTANE 500 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF PATIENTS WITH INOPERABLE, FUNCTIONAL OR NONFUNCTIONAL, ADRENAL CORTICAL CARCINOMA. |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
02 L 1062/24 |
20-FEB-2024 |
19-FEB-2027 |
View |
| 1752 |
LUCIMOB |
MOBOCERTINIB 40 MG |
CAPSULE |
BOTTLE |
TREATMENT OF ADULT WITH LOCALLY ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
07 L 0993/23 |
31-JUL-2023 |
30-JUL-2026 |
View |
| 1753 |
LUCIMOMEL |
MOMELOTINIB 100 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS INCLUDING PRIMARY MF OR SECONDARY MF, POST ESSENTIAL THROMBOCYTHEMIA IN ADULT WITH ANEMIA. |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
06 L 1113/24 |
21-JUN-2024 |
20 JUN 2027 |
View |
| 1754 |
LUCINERA |
NERATINIB 40 MG |
TABLET |
BOTTLE |
FOR THE EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HER2 POSITIVE BREAST CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
09 L 1225/24 |
31-OCT-2024 |
30-OCT-2029 |
View |
| 1755 |
LUCINFIG |
INFIGRATINIB 100 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED ORMETASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 FUSION OR OTHER REARRANGEMENT |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
04 L 1338/25 |
27-MAY-2025 |
26-MAY-2030 |
View |
| 1756 |
LUCINFIG |
INFIGRATINIB 25 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED ORMETASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 FUSION OR OTHER REARRANGEMENT |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
04 L 1339/25 |
2025-04-21 |
2030-04-20 |
View |
| 1757 |
LUCINFIG |
INFIGRATINIB 100 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED ORMETASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 FUSION OR OTHER REARRANGEMENT |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
04 L 1338/25 |
2025-04-21 |
2030-04-20 |
View |
| 1758 |
LUCINIRA |
NIRAPARIB 100 MG |
TABLET |
BOTTLE |
FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH ADVANCED EPITHELIAL OVRIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST LINE PLATIUM BASED CHEMOTHERAPY |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
12 L 1280/24 |
23-JAN-2025 |
22-JAN-2030 |
View |
| 1759 |
LUCIOB |
OBETICHOLIC ACID 5 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH PRIMARY BILIARY CHOLANGITIS WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS WHO DO NOT HAVE EVIDENCE OF PORTAL HYPERTENSION, EITHER IN COMBINATION WITH URSODEOXYCHOLIC ACID WITH AN INADEQUATE RESPONSE TO UDCA OR AS MONOTHERAPY IN PATIENTS UNBALE TO TOLERATE URSODEOXYCHOLIC ACID |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
03 L 1318/25 |
07-APR-2025 |
06-APR-2030 |
View |
| 1760 |
LUCIODEVI |
ODEVIXIBAT 400 MCG |
CAPSULE |
BOTTLE |
PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
12 L 1278/24 |
2025-04-21 |
2030-04-20 |
View |
